Evidence map›Paper›PMID 42028639›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Bioorthogonal Fluorogenic Reporters for Noninvasive Imaging and Urinalysis of Immunotherapeutic Response in Renal Cell Carcinoma.

Xingyue Yang, Baoshuai Liang, Liangmin Fu, Weiliang Deng, Yuyan Jiang, Weiping Xu, Jinwei Chen, Ya Zhou, Ke Wu, Jiaguo Huang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Xingyue YangState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Baoshuai LiangState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Liangmin FuDepartment of Urology, The Second Xiangya Hospital of Central South University, Changsha, China.
Weiliang DengState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Yuyan JiangDepartment of Radiation Oncology, Stanford University School of Medicine, Stanford, California, USA.
Weiping XuState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.
Jinwei ChenDepartment of Urology, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
Ya ZhouDepartment of Pharmacy, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing, China.
Ke WuDepartment of Pharmacy, The Affiliated Dazu's Hospital of Chongqing Medical University, Chongqing, China.
Jiaguo HuangState Key Laboratory of Anti-Infective Drug Discovery and Development, School of Pharmaceutical Sciences, Sun Yat-sen University, Guangzhou, China.ORCID https://orcid.org/0000-0003-4012-4406

Funding

China Postdoctoral Science Foundation 2024M763793Guangzhou Municipal Science and Technology Project 2025A04J7148introduced innovative R&D team project of "The Pearl River Talent Recruitment Program" 2021ZT09Y544Key Research and Development Plan of Guangzhou City 202206080007Medical Scientific Research Foundation of Guangdong Province of China A2025206National Key R&D Program of China 2022YFA0912700National Natural Science Foundation of China 22207130National Natural Science Foundation of China 22474160National Natural Science Foundation of China 82503496the start-up funding of the affiliated Dazu's hospital of chongqing medical university 2025KYF001
6 · The paper itself

Abstract

Real-time monitoring of kidney-infiltrating cytotoxic T lymphocytes (CTLs) is crucial for evaluating immunotherapy in renal cell carcinoma (RCC). However, existing imaging probes often exhibit "always-on" signals and poor renal clearance, limiting their ability to detect renal immune responses. Herein, we report renal-clearable bio-orthogonal near-infrared (NIR) fluorogenic probes (BGRs) that specifically detect granzyme B (GzmB), a biomarker of CTL activation, for dynamic evaluation of RCC immunotherapy. BGRs are built on a nitrile-substituted hemicyanine scaffold with a biothiol-responsive cysteine tail that is dually locked with a GzmB-responsive peptide and conjugated to renal clearable (2-hydroxypropyl)-β-cyclodextrin (HPβCD). Following injection in RCC mouse models under immunotherapy, non-fluorescent BGR

Indexed as

Carcinoma, Renal CellFluorescent DyesImmunotherapyKidney NeoplasmsUrinalysisAnimalsCell Line, TumorDisease Models, AnimalFemaleFluorescent Chemosensor CompoundsGranzymesHumansMiceT-Lymphocytes, CytotoxicFluorescent Chemosensor CompoundsFluorescent DyesGranzymesbioorthogonal chemistryimmunotherapyNIRF imagingrenal cell carcinomaurinalysis

Identifiers

PMID42028639
PMCPMC13335466

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.